 Eperisone suffers from a very low bioavailability when taken orally, as a result of high first pass intestinal metabolism; a transdermal patch containing eperisone is currently in development in South Korea.This has shown promise, with the antispasmodic effect lasting over 24 hours, compared to one to two hours following oral administration.Eperisone is also under investigation as an antihypertensive agent, with promising results from trials on beagles.